Literature DB >> 2925571

Neurochemical study of dopamine functioning in autistic and normal subjects.

R B Minderaa, G M Anderson, F R Volkmar, G W Akkerhuis, D J Cohen.   

Abstract

Plasma prolactin (PRL) and homovanillic acid (HVA) levels, and urinary HVA and dopamine (DA) excretion, were measured in groups of unmedicated autistics, medicated autistics, and normal controls. No significant differences were found between unmedicated autistics and normal controls in plasma PRL and HVA levels. Excretion rates of urinary HVA and DA were also similar in the unmedicated autistic and normal subjects. Plasma PRL and HVA, as well as urinary HVA excretion, were significantly increased in the autistics on neuroleptic medication compared to the unmedicated autistics. A significant correlation (r = 0.46, p = less than 0.05) was observed between dose of neuroleptics and plasma PRL values; the correlation (r = 0.42) between neuroleptic dose and plasma HVA levels approached significance (p = 0.06). In contrast, no differences were observed in urinary DA excretion between medicated and unmedicated autistics. In general, the findings indicate that peripheral indices of dopamine functioning are normal in autistic subjects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2925571     DOI: 10.1097/00004583-198903000-00007

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  9 in total

Review 1.  Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy.

Authors:  J K Buitelaar; S H Willemsen-Swinkels
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 2.  Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.

Authors:  Logan K Wink; Martin H Plawecki; Craig A Erickson; Kimberly A Stigler; Christopher J McDougle
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

3.  Investigation of whole blood and urine monoamines in autism.

Authors:  Josiane Hérault; Joëlle Martineau; Anne Perrot-Beaugerie; Jacqueline Jouve; Hervé Tournade; Catherine Barthelemy; Gilbert Lelord; Jean-Pierre Muh
Journal:  Eur Child Adolesc Psychiatry       Date:  1993-10       Impact factor: 4.785

Review 4.  Medication treatment in subjects with autistic spectrum disorders.

Authors:  J K Buitelaar; S H Willemsen-Swinkels
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

5.  Growth hormone response to L-dopa and clonidine in autistic children.

Authors:  G M Realmuto; J B Jensen; E Reeve; B D Garfinkel
Journal:  J Autism Dev Disord       Date:  1990-12

Review 6.  Modeling dopamine dysfunction in autism spectrum disorder: From invertebrates to vertebrates.

Authors:  Gabriella E DiCarlo; Mark T Wallace
Journal:  Neurosci Biobehav Rev       Date:  2021-12-11       Impact factor: 8.989

7.  Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function.

Authors:  S Dollfus; M Petit; J F Menard; P Lesieur
Journal:  J Autism Dev Disord       Date:  1992-03

Review 8.  Antipsychotics in the treatment of autism.

Authors:  David J Posey; Kimberly A Stigler; Craig A Erickson; Christopher J McDougle
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

9.  Effects of Physical Exercise on the Stereotyped Behavior of Children with Autism Spectrum Disorders.

Authors:  José Pedro Ferreira; Thaysa Ghiarone; Cyro Rego Cabral Júnior; Guilherme Eustáquio Furtado; Humberto Moreira Carvalho; Aristides Machado Rodrigues; Chrystiane Vasconcelos Andrade Toscano
Journal:  Medicina (Kaunas)       Date:  2019-10-14       Impact factor: 2.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.